Home > Healthcare > Pharmaceuticals > Finished Drug Form > Albumin Market
Albumin Market was valued at USD 5.6 billion in 2023 and is set to register more than 6.5% CAGR between 2024 and 2032. The increasing prevalence of chronic diseases, growing non-therapeutic applications of albumin, increase in demand for albumin in R&D activities, and technological advancements in biotechnology significantly influence the market growth.
Demand for albumin is growing, especially for treatments involving volume expansion, shock, burns, and other medical conditions requiring plasma derived therapy or protein supplementation. For instance, according to the American Burn Association, in U.S. approximately 450,000 patients receive hospital or emergency room treatment for burns each year. The burn injuries necessitate extensive use of albumin for fluid resuscitation, edema reduction, and therapeutic management. The high incidence of burns globally, coupled with advancements in burn care that improve survival rates, ensures a steady demand for albumin.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Albumin Market Size in 2023: | USD 5.6 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2024 to 2032 CAGR: | 6.5% |
2032 Value Projection: | USD 10.1 Billion |
Historical Data for: | 2018 – 2023 |
No. of Pages: | 176 |
Tables, Charts & Figures: | 309 |
Segments covered: | Product, Application, End-user, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Albumin, a major protein found in blood plasma, has a wide range of applications in healthcare, including therapeutic use for conditions such as hypovolemia, burns, shock, liver disease, and nephrotic syndrome. Additionally, albumin is utilized in drug formulation, drug delivery systems, diagnostic assays, and research applications in fields such as biotechnology, life sciences, and regenerative medicine.